Aridis Pharmaceuticals, Inc. announced that it has appointed Paul Mendelman, MD as interim Chief Medical Officer (CMO). Dr. Mendelman replaces Dr. Wolfgang Dummer who has departed the company for personal reasons. Dr. Mendelman brings to Aridis a prolific career in infectious diseases across industry and academia spanning over 30 years with board certification in pediatrics and pediatric infectious diseases. Dr. Mendelman's initial priority will be to manage the Company's ongoing Phase 3 for AR-301 in patients with ventilator associated pneumonia (VAP) and the ongoing Phase 1/2a for AR-501 in patients with cystic fibrosis. He will also work closely with the Aridis team in overseeing the ongoing analysis of results from the Company's recent AR-105 Phase 2 for the treatment of VAP caused by gram-negative Pseudomonas aeruginosa. Dr. Mendelman replaces Dr. Wolfgang Dummer who has departed the company for personal reasons.